Authors: MAST AE BLINDER MA GRONOWSKI AM CHUMLEY C SCOTT MG

Citation: Ae. Mast et al., CLINICAL UTILITY OF THE SOLUBLE TRANSFERRIN RECEPTOR AND COMPARISON WITH SERUM FERRITIN IN SEVERAL POPULATIONS, Clinical chemistry, 44(1), 1998, pp. 45-51

Authors: MAST AE HIGUCHI DA HUANG ZF WARSHAWSKY I SCHWARTZ AL BROZE GJ

Citation: Ae. Mast et al., GLYPICAN-5 IS A BINDING-PROTEIN ON THE HEPG2 CELL-SURFACE FOR TISSUE FACTOR PATHWAY INHIBITOR, Biochemical journal, 327, 1997, pp. 577-583

Authors: MAST AE HUANG ZF WARSHAWSKY I SCHWARTZ AL BROZE GJ

Citation: Ae. Mast et al., GLYPICAN-3 IS A TISSUE FACTOR PATHWAY INHIBITOR BINDING-PROTEIN ON THE HEPG2 CELL-SURFACE, Blood, 88(10), 1996, pp. 1866-1866

Authors: MAST AE BROZE GJ

Citation: Ae. Mast et Gj. Broze, PHYSIOLOGICAL CONCENTRATIONS OF TISSUE FACTOR PATHWAY INHIBITOR DO NOT INHIBIT PROTHROMBINASE, Blood, 87(5), 1996, pp. 1845-1850

Authors: DENGLER R LOTTSPEICH F OBERTHUR W MAST AE EMMERICH B

Citation: R. Dengler et al., LIMITED PROTEOLYSIS OF ALPHA(1)-PROTEINASE INHIBITOR (ALPHA(1)-PL) INACUTE-LEUKEMIA - STUDIES ON THE RESULTING FRAGMENTS AND IMPLICATION FOR THE STRUCTURE OF THE INACTIVATED INHIBITOR, Biological chemistry Hoppe-Seyler, 376(3), 1995, pp. 165-172

Authors: MAST AE BLINDER MA GRONOWSKI A CHUMLEY C SCOTT MG

Citation: Ae. Mast et al., THE CLINICAL UTILITY OF THE SERUM TRANSFERRIN RECEPTOR LEVEL IN THE EVALUATION OF IRON-DEFICIENCY ANEMIA, Blood, 86(10), 1995, pp. 498-498